ROUND ROCK, Texas, May 5, 2021 /PRNewswire/ --
News summary
- COVID-19 Long haulers study to create personalized health risk
scores and drug treatment recommendations based on patients' unique
medical history and genetics
- AI-driven research and digital twins will support hospitals and
research centers globally and contribute to Dell's goal to use
technology and scale to advance health, education and economic
opportunity for 1 billion people by 2030
Full story
Dell Technologies (NYSE:DELL) is helping i2b2 tranSMART
Foundation, a non-profit open-source research organization,
mobilize huge amounts of global de-identified patient data to
create virtual models of patients – known as digital twins – to
treat impacts of long-haul COVID-19.
Through Dell Technologies' modern infrastructure, the i2b2
tranSMART community will use de-identified patient data to produce
digital twins. Researchers can then perform millions of
individualized treatment simulations on the digital twins to
determine the best possible therapy option for patients, based on
genetic background and medical history.
To make this possible and provide the
computational, artificial intelligence, machine learning
and advanced storage capabilities to generate digital twins, Dell
Technologies built a data enclave – a secure data storage network –
comprised of Dell EMC PowerEdge, PowerStore and PowerScale
storage systems, as well as VMware Workspace ONE and
Boomi integration services. In the data enclave, researchers
gather, store and analyze data scattered across various
monitoring systems and electronic health records and in the future
will have the capability to update the digital twins
with real-time clinical data collected through ventilator and
cardiac monitors.
"This project is a perfect example of the global research and
technology community coming together to support people who are
suffering from a condition that is not well understood," said
Jeremy Ford, vice president of
strategic giving and social innovation, Dell Technologies. "Working
together with the i2b2 tranSMART Foundation, we will
apply our expertise and technology to build digital
twins, share data, conduct simulations and analyses – using these
insights to help understand and better treat patients with
long-haul COVID."
Initially, researchers will use the data enclave to power
70,000 patients' tests, simulations and analyses,
which will be shared with the 4CE Consortium, an
international coalition of more than 200 hospitals and research
centers including data collaboratives across the US,
France, Germany, Italy, Singapore, Spain, Brazil, India
and the United Kingdom. This effort has the potential to
expand with data for up to two million digital twins in the next
four years.
Understanding and treating long-haul COVID
An estimated 1 in 20 people with COVID-19 are likely to
experience long-term symptoms, ranging from profound fatigue, brain
fog, headaches, cardiac arrhythmia, fevers and shortness of breath.
So-called long haulers suffer from what is known formally as
Post-Acute Sequelae of SARS-CoV-2 (PASC). Little is known about why
some continue to be affected after the virus has left the
body or about the long-term impacts.
To learn more, The National Institutes of
Health recently announced the first phase of a
four-year, billion-dollar initiative to support PASC research.
Research on this condition requires colossal amounts of
patient data. Working directly with the 4CE Consortium, the i2b2
tranSMART Foundation has supported the mobilization of data
from a network of more than 200 institutions worldwide. To
protect the privacy of patients, all data is de-identified before
it is submitted to the 4CE Consortium.
"At this stage, healthcare professionals are breaking new ground
by developing and evaluating the efficacy of COVID-19 treatments,"
said Dr. Shawn Murphy, i2b2 tranSMART Foundation board member.
"This new AI-driven platform will help them use the explosion of
research findings to deliver better care and precision treatments
for their patients. By creating these digital twins, we are taking
clinical research to a whole new level."
Additional resources
- Blog: How the Power of AI is Helping
COVID-19 Long-Haulers
- Infographic: Digital Twin 'Long Hauler' Research
- Progress Made Real social impact plan and 2030 goals
About Dell Technologies
Dell Technologies (NYSE:DELL) helps organizations and
individuals build their digital future and transform how they work,
live and play. The company provides customers with the industry's
broadest and most innovative technology and services portfolio for
the data era.
About Dell Technologies World
Join us May 5-6 for the Dell
Technologies World Experience, the company's flagship event that
brings together latest emerging trends, technology and gurus.
During the event, we will demonstrate to customers and partners the
connected ecosystem of IT infrastructure, applications, devices and
security. Learn more about the Dell Technologies Project APEX
as-a-Service portfolio that gives customers greater flexibility to
scale IT to meet business needs and budgets.
Register here.
Copyright © 2021 Dell Inc. or its subsidiaries. All Rights
Reserved. Dell Technologies, Dell, EMC and Dell EMC are trademarks
of Dell Inc. or its subsidiaries. Other trademarks may be
trademarks of their respective owners.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/dell-technologies-and-i2b2-transmart-foundation-create-digital-twins-to-treat-long-haul-covid-19-301284633.html
SOURCE Dell Technologies